Novozymes, Cargill Continue Bio-Acrylic Acid Partnership as BASF Exits
News Jan 28, 2015
Chemical company BASF has decided to exit the current R&D collaboration with Novozymes and Cargill to develop a bio-based process for producing 3-hydroxypropionic (3-HP) and acrylic acid from renewable raw materials.
Germany based BASF joined the collaboration with Novozymes and Cargill in 2012 and are now leaving the partnership. Novozymes and Cargill have collaborated on the project since 2008 and will continue their work to commercialize bio-based 3-HP and derivatives. The two companies have initiated efforts to find a new commercialization partner.
“We are continuing our work with Novozymes to commercialize 3-HP to bio-based chemicals, including acrylic acid to bring our customers more sustainable alternatives to fossil-based chemicals,” says Cargill’s Vice President of Research and Development, Jack Staloch.
“This is pioneering biochemical research, and the technology development and achievements so far have been extraordinary,” says Kristian Bjørneboe, Vice President for Business Creation and Acquisition at Novozymes.
Technical and business targets achieved
The R&D cooperation on bio-based acrylic acid has achieved the technical and business targets. In 2013, the project accomplished the production of 3-HP in pilot scale, and in September 2014 announced the successful conversion of 3-HP to glacial acrylic acid and superabsorbent polymers.
Acrylic acid is a high-volume chemical that feeds into a broad range of products. One of the main applications is in the manufacture of superabsorbent polymers that can soak up large amounts of liquid and are used mainly in baby diapers and other hygiene products.
Acrylic acid is also used in adhesive raw materials and coatings. Presently, acrylic acid is produced by the oxidation of propylene derived from the refining of crude oil.
Abzena Selects Sartorius Stedim Biotech to Equip its US Based Development and Manufacturing SitesNews
Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.READ MORE
Emergex Awarded Innovate UK Grant to Progress its Universal and Pandemic Flu VaccineNews
Emergex Vaccines Holding Limited, a biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, announces that Innovate UK, the UK’s innovation agency, has awarded the company a grant of £979,318 to progress its universal flu vaccine programme through preclinical development.READ MORE
Porvair Sciences Makes Strategic Appointment for US Microplate BusinessNews
Porvair Sciences and J.G. Finneran Associates are pleased to announce the appointment of Bob Brino as OEM Business Development Manager for their microplate and sample prep product lines.READ MORE
Comments | 0 ADD COMMENT
World Congress on Bio-organic and Medicinal Chemistry
Nov 12 - Nov 13, 2018